Pazufloxacin opthalmic - Laboratorios Sophia

Drug Profile

Pazufloxacin opthalmic - Laboratorios Sophia

Alternative Names: PRO-157; Project-157

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator Laboratorios Sophia
  • Class Antibacterials; Fluoroquinolones; Oxazines; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Infectious conjunctivitis

Most Recent Events

  • 01 Mar 2015 Phase-II clinical trials in Infectious conjunctivitis (In children, In adults, In the elderly) in Mexico (Ophthalmic) (NCT02980523)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top